Patent ID: 6670376
Filing Date: 2003-12-30
Classification: A61P,C07C,C07D

Abstract:
A compound of formula (I): wherein:each of R1-R5 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, and Ra; or R1 and R2, R2 and R3, R3 and R4, or R4 and R5 are joined together to form a group selected from the group consisting of â€”C(Rd)&boxH;C(Rd)C(&boxH;O)NRdâ€”, â€”CRdRdâ€”CRdRdâ€”C(&boxH;O)NRdâ€”, â€”NRdC(&boxH;O)C(Rd)&boxH;C(Rd), â€”NRdC(&boxH;O)CRdRdâ€”CRdRdâ€”, â€”NRdC(&boxH;O)Sâ€”, â€”SC(&boxH;O)NRdâ€”, â€”(CRdRd)pâ€”, â€”S(CRdRd)qâ€”, â€”(CRdRd)qSâ€”, â€”S(CRdRd)rOâ€”, â€”O(CRdRd)rSâ€”, and â€”NHC(Rj)&boxH;C(Rk)â€”; R6 is hydrogen, alkyl, or alkoxy; R7 is hydrogen or alkyl; R8 is hydrogen or alkyl; or R8 together with R9 is â€”CH2â€” or â€”CH2CH2â€”; R9 is independently selected from the group consisting of alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, and Ra, or R9 together with R8 is â€”CH2â€” or â€”CH2CH2â€”; R10 is hydrogen or alkyl; each R11, R12, and R13 is independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, â€”NO2, halo, â€”NRdRe, â€”C(&boxH;O)Rd, â€”CO2Rdâ€”OC(&boxH;O)Rd, â€”CN, â€”C(&boxH;O)NRdRe, â€”NRdC(&boxH;O)Re, â€”OC(&boxH;O)NRdRe, â€”NRdC(&boxH;O)ORe, â€”NRdC(&boxH;O)NRdRe, â€”ORd, â€”S(O)mRd, â€”NRdâ€”NRdâ€”C(&boxH;O)Rd, â€”NRdâ€”N&boxH;CRdRd, â€”N(NRdRe)Rd, and â€”S(O)2NRdRe; or R11 and R12 together with the atoms to which they are attached form a fused benzo ring, which benzo ring can optionally be substituted with 1, 2, 3, or 4 Rc; or R11 and R12 together with the atoms to which they are attached form a heterocyclic ring; wherein for R1-R6, R9, and R11-R13, each alkyl, alkenyl, and alkynyl is optionally substituted with Rm, or with 1, 2, 3, or 4 substituents independently selected from Rb; for R1-R6, R9, and R11-R13, each aryl and heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rc, and for R1-R6, R9, and R11-R13 each cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rb and Rc; each Ra is independently â€”ORd, â€”NO2, halo, â€”S(O)mRd, â€”S(O)2ORd, â€”S(O)mNRdRe, â€”NRdRe, â€”O(CRfRg)nNRdRe, â€”C(&boxH;O)Rd, â€”CO2Rd, â€”CO2(CRfRg)â€”CONRdRe, â€”OC(&boxH;O)Rd, â€”CN, â€”C(&boxH;O)NRdRe, â€”NRdC(&boxH;O)Re, â€”OC(&boxH;O)NRdRe, â€”NRdC(&boxH;O)ORe, â€”NRdC(&boxH;O)NRdRe, â€”CRd(&boxH;Nâ€”ORe), â€”CF3, or â€”OCF3; each Rb is independently Ra, oxo, or &boxH;Nâ€”ORc; each Rc is independently Ra, alkyl, alkenyl, or alkynyl; wherein each alkyl, alkenyl and alkynyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rb; each Rd and Re is independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; wherein each alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh; or Rd and Re together with the atoms to which they are attached form a heterocyclic ring having from 5 to 7 ring atoms, wherein the heterocyclic ring optionally contains 1 or 2 additional heteroatoms independently selected from oxygen, sulfur or nitrogen; each Rf and Rg is independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclyl; wherein each alkyl, aryl, heteroaryl, cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents independently selected from Rh; or Rf and Rg together with the carbon atom to which they are attached form a ring having from 5 to 7 ring atoms, wherein the ring optionally contains 1 or 2 heteroatoms independently selected from oxygen, sulfur or nitrogen; each Rh is independently halo, C1-8alkyl, C1-8alkoxy, â€”Sâ€”C1-8alkyl, aryl, (aryl)-C1-6alkyl, (aryl)-C1-8alkoxy, heteroaryl, (heteroaryl)-C1-6alkyl, (heteroaryl)-C1-8alkoxy, hydroxy, amino, â€”NHC1-6alkyl, â€”N(C1-6alkyl)2, â€”OC(&boxH;O)C1-6alkyl, â€”C(&boxH;O)C1-6 halkyl, â€”C(&boxH;O)OC1-6alkyl, â€”NHC(&boxH;O)C1-6alkyl, â€”C(&boxH;O)NHC1-6alkyl, carboxy, nitro, â€”CN, or â€”CF3; Rj and Rk together with the carbon atoms to which they are attached form a phenyl ring that is optionally substituted with 1, 2, 3, or 4 Rc; each Rm is independently aryl, heteroaryl, cycloalkyl or heterocyclyl; wherein each aryl or heteroaryl is optionally substituted with 1, 2, 3, or 4 substituents selected from the group consisting of Rc, and wherein each cycloalkyl and heterocyclyl is optionally substituted with 1, 2, 3, or 4 substituents selected from Rb; m is 0, 1, or 2; n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; p is 3, 4, or 5; q is 2, 3, or 4; r is 1, 2, or 3; and w is 0, 1, 2, 3, or 4; or a pharmaceutically-acceptable salt or solvate or stereoisomer thereof.